-
Associate Professor Jingjie Zhao: Standardized Design and Implementation Using Recognized Endpoint Indicators to Provide High-Quality Evaluation for TCM Intervention in Metabolic-Associated Fatty Liver Disease Research
On May 18, 2024, the “25th National Academic Conference on Traditional Chinese Medicine for Hepatobiliary Diseases” was successfully held in Chongqing. The conference invited masters of Chinese medicine, academicians, nationally renowned TCM doctors, and leading experts in hepatology from both traditional Chinese and Western medicine to present academic reports. The focus was on hot and…
-
Chairman Interview丨Professor Chunjun Xu: A Holistic Approach to the Treatment of Primary Liver Cancer
Primary liver cancer is currently the 4th most common malignant tumor and the 2nd leading cause of cancer-related death in China, posing a serious threat to the life and health of the Chinese people. Traditional Chinese Medicine (TCM) has extensive clinical experience in treating primary liver cancer, using a syndrome differentiation approach at different stages…
-
Machine Learning Prognostic Model for Epstein-Barr Virus Reactivation after Haploidentical Hematopoietic Stem Cell Transplantation
In January 2023, a study led by Professor Xiao Jun Huang from Peking University People’s Hospital was published in the international academic journal ——Blood Science . The title of the study is “Machine learning algorithm as a prognostic tool for Epstein-Barr virus reactivation after haploidentical hematopoietic stem cell transplantation”. This study elucidates the machine learning…
-
Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins
In July 2023, a study led by Professor Zhijian Xiao from Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College was published in the international academic journal ——Blood Science . The title of the study is “Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via…
-
EBMT Exclusive Interview | Professor Yanmin Zhao: Maintenance Treatment Strategies for FLT3-ITD Mutant AML Patients After Transplantation
FMS-like tyrosine kinase 3 (FLT3) mutations, particularly internal tandem duplication mutations (FLT3-ITD), are one of the significant factors affecting the prognosis of patients with acute myeloid leukemia (AML). Overcoming the challenge of relapse after transplantation in patients with FLT3-mutated AML remains a significant clinical hurdle. At the 50th European Bone Marrow Transplantation (EBMT) annual meeting,…
-
Digital Management of Chronic Progressive Liver Disease in China: Monthly Literature Review (April 2024, Issue 80)
Hello, esteemed experts and colleagues. In this issue of the CDM Monthly Review (Issue 80), we will share six recent articles on the diagnosis and treatment of portal hypertension (four on diagnosis and monitoring, and two on multidisciplinary treatment). We have invited the following experts to review this month’s issue: Dr. Yifei Huang from the…
-
Professor Shichun Lu’s Team: Proportion of Viable Tumor Cells Predicts Prognosis of Targeted Immunotherapy for Liver Cancer
Recently, Professor Shichun Lu’s team from the Chinese PLA General Hospital published an article titled “Application of Proportion of Viable Tumor Cells in Prognosis Evaluation of Initial Unresectable Hepatocellular Carcinoma Patients Undergoing Sequential Surgical Treatment After Conversion Therapy” in the professional journal Chinese Journal of Hepatobiliary Surgery. The study retrospectively analyzed clinical data and pathological…
Connecting Medical Expertise through Media
